Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
Antiestrogen vs Aromatase Inhibitor After Chemotherapy for Adjuvant Setting: Efficacy of Endocrine Therapy After Chemotherapy in Postoperative Adjuvant Therapy for Breast Cancer
Sponsor: Japan Breast Cancer Research Network
Terminated
This trial was terminated. No reason was provided.
A PHASE2 clinical study on Breast Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Japan Breast Cancer Research Network and has accumulated 5 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Japan Breast Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .